{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:19:48Z","timestamp":1788448788778,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.critrevonc.2019.07.012","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T11:23:30Z","timestamp":1563794610000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Systemic therapy for brain metastases"],"prefix":"10.1016","volume":"142","author":[{"given":"Jonathan W","family":"Rick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-3894","authenticated-orcid":false,"given":"Ankush","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Dalle Ore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-7722","authenticated-orcid":false,"given":"John K.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Yagnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Arfaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-2227","authenticated-orcid":false,"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.07.012_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200216050-00005","article-title":"Brain metastases: treatment options to improve outcomes","volume":"16","author":"Davey","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.03.018","article-title":"Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms","volume":"126","author":"Nieder","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0733-8619(02)00035-X","article-title":"Brain metastases","volume":"21","author":"Lassman","year":"2003","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0025","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J. Med. Life"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-015-0028-8","article-title":"Breast cancer brain metastases: the last frontier","volume":"4","author":"Leone","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rpor.2011.01.002","article-title":"Characteristics of long-term survivors of brain metastases from lung cancer","volume":"16","author":"Niemiec","year":"2011","journal-title":"Reports Pract. Rep. Pract. Oncol. Radiother."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01052723","article-title":"A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors","volume":"20","author":"Stewart","year":"1994","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0050","first-page":"1115","article-title":"Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice","volume":"141","author":"Zhang","year":"1992","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00686291","article-title":"Do anticancer agents reach the tumor target in the human brain?","volume":"30","author":"Donelli","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1042-3680(18)30378-4","article-title":"Chemotherapy of cerebral metastases from solid tumors","volume":"7","author":"Lesser","year":"1996","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0065","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non\u2013small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0070","first-page":"273","article-title":"Molecular determinants of lung cancer metastasis to the central nervous system","volume":"2","author":"Whitsett","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0075","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit Cancer surveillance system","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0080","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung Cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3816\/CLC.2008.n.006","article-title":"Chemotherapy for brain metastases in small-cell lung Cancer","volume":"9","author":"Chen","year":"2008","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1023\/A:1008318515795","article-title":"Chemotherapy for brain metastases of lung cancer: a review","volume":"10","author":"Postmus","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/bjc.1990.30","article-title":"The response of cerebral metastases in small cell lung cancer to systemic chemotherapy","volume":"61","author":"Twelves","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/oxfordjournals.annonc.a058592","article-title":"Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen","volume":"4","author":"Kristjansen","year":"1993","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007464.pub2","article-title":"Chemotherapy for brain metastases from small cell lung cancer","author":"Reveiz","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0110","first-page":"5797","article-title":"Brain metastases in NSCLC - are TKIs changing the treatment strategy?","volume":"35","author":"Dempke","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0115","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx782","article-title":"LBA5CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study","volume":"28","author":"Vansteenkiste","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -Mutated advanced non\u2013Small-Cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0125","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK -Positive lung Cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX trial investigators, alectinib versus crizotinib in untreated ALK -Positive non\u2013Small-Cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-012-0213-4","article-title":"The biology and clinical features of non\u2013small cell lung cancers with EML4-ALK translocation","volume":"14","author":"Pillai","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0140","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-Positive non-small-Cell lung Cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0145","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.03.47","article-title":"ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements","volume":"5","author":"Tran","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0150","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","article-title":"Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non\u2013Small-Cell lung Cancer","volume":"31","author":"Welsh","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0170","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK -Rearranged non\u2013Small-Cell lung Cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0175","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.semcancer.2018.01.015","article-title":"Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment","volume":"52","author":"Passiglia","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0185","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.critrevonc.2018.05.013","article-title":"Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?","volume":"128","author":"Frega","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0195","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","article-title":"Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma","volume":"94","author":"Schouten","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archneur.1977.00500210025002","article-title":"Chemotherapy of brain tumors","volume":"34","author":"Vick","year":"1977","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0205","first-page":"307","article-title":"Breast cancer brain metastases: new directions in systemic therapy","volume":"7","author":"Lin","year":"2013","journal-title":"Ecancermedicalscience."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091543","article-title":"Targeted therapies for brain metastases from breast Cancer","volume":"17","author":"Venur","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0215","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W","article-title":"Chemotherapy induces regression of brain metastases in breast carcinoma","volume":"58","author":"Rosner","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/030089169307900516","article-title":"Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases","volume":"79","author":"Salvati","year":"1993","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0225","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1470-2045(04)01558-X","article-title":"High incidence of brain metastases with trastuzumab treatment","volume":"5","author":"Burton","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/030089169307900516","article-title":"Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases","volume":"79","author":"Salvati","year":"1993","journal-title":"Tumori."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0235","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1200\/JCO.2012.44.8894","article-title":"Intrathecal trastuzumab halts progression of CNS metastases in breast Cancer","volume":"34","author":"Bousquet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0240","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast Cancer That overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2014 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","article-title":"HER2-positive breast cancer: Current and new therapeutic strategies","volume":"39","author":"Escriv\u00e1-de-Roman\u00ed","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12885-018-3994-5","article-title":"Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review","volume":"18","author":"Ricciardi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0260","first-page":"43","article-title":"Activity of TRASTUZUMAB-EMTANSINE (TDM1) in HER2-POSITIVE breast cancer brain metastases: a case series","volume":"7","author":"Keith","year":"2016","journal-title":"Cancer Treat. Commun."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0265","article-title":"Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: a single institution experience","author":"Okines","year":"2017","journal-title":"Breast J."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0270","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","article-title":"Activity of T-DM1 in Her2-positive breast cancer brain metastases","volume":"32","author":"Bartsch","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.07.024","article-title":"The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis","volume":"84","author":"Petrelli","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0280","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0290","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccell.2015.01.001","article-title":"Emerging strategies for treating brain metastases from breast Cancer","volume":"27","author":"Kodack","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1042-3680(18)30365-6","article-title":"Demographics of brain metastasis","volume":"7","author":"Johnson","year":"1996","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0300","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JOP.2016.011882","article-title":"Management of brain metastases in patients with melanoma","volume":"12","author":"Chukwueke","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0305","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-015-0442-6","article-title":"Nivolumab: a review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0320","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0325","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0335","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12943-017-0645-4","article-title":"The landscape of BRAF transcript and protein variants in human cancer","volume":"16","author":"Marranci","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0340","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","article-title":"Pathways and therapeutic targets in melanoma","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0345","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0350","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0355","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.012_bib0360","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:30:59Z","timestamp":1760902259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819301465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":72,"alternative-id":["S1040842819301465"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.012","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy for brain metastases","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}